Drugstore operator CVS Caremark (NYSE:CVS) announced third quarter earnings growth of 7% over the 2010 quarter. In addition, the company forecasted a more favorable 2011 driven by growth in the number of pharmacy claims the company processed. A solid quarter and a forecast for an even better year, should be the beginning of a quality growth cycle for CVS.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Future Growth Ahead
CVS reported a net income of $868 million, or 65 cents a share, compared with a net income of $809 million, or 59 cents a share, in the year ago 2010 period. Analysts were expecting earnings of 67 cents, not accounting for expenses related to acquisitions. Absent those expenses, CVS could be earning 70 cents per share. Profit growth was accompanied by a healthy 12% increase in sales quarter over quarter. CVS benefited from strong growth in its pharmacy benefits business, fueled by the acquisitions of Caremark and the Medicare business from Universal American. Those acquisitions have enabled CVS to directly negotiate lower prescription prices with drug manufacturers. Caremark is expected to add over $8 billion in top line growth in 2011, while the Universal American deal will add over $5 billion in sales in 2012. The company's retail drugstores grew sales by 4% quarter over quarter, while same-store sales, the true measure of retailing health, grew 2.3%, respectively. As the pharmacy business fuels prescription growth, increased store traffic should fuel drugstore growth. (For related reading, see Consumer Spending As A Market Indicator.)

Recession Proof Business
CVS is the second largest drugstore chain operator in the U.S. The largest is rival Walgreen (NYSE:WAG). Together, CVS and WAG operate in a near duopolistic industry. Much smaller rival, Rite-Aid (NYSE:RAD) has been struggling under a pile of debt. CVS currently has over 7,300 locations, while Walgreen's operates over 8,200 locations. Rite-Aid's 4,700 stores would make a decent acquisition, except for the fact that company sits on over $6 billion in debt. Moreover, CVS has been building new locations and taking advantage of cheaper building and construction costs.

With the U.S. population aging, prescription drug demand is expected to grow for years. As CVS continues to benefit from the growth, in its pharmacy benefits business, the company's top and bottom line will likely continue to grow. For 2012, the analysts expect earnings per share of $3.18, but could very likely exceed that guidance. Low prices from Wal-Mart (NYSE:WMT) is not a threat, since CVS can sell generics at the same price. The edge that CVS and Walgreen's have over Wal-Mart is that they have smaller stores, which are often a shorter driving distance than the nearest Wal-Mart. The convenience factor is a valuable one.

The Bottom Line
Trading at about 15 times trailing earnings, CVS has a very reasonable valuation for such a solid business. Prescription drug demand is growing due to a growing aging population. Healthcare is not an economically sensitive product, and will not be drastically affected by any economic setbacks. That gives the company resilience in an uncertain economy. (For related reading, see How To Do Qualitative Analysis On Biotech Companies.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Sham Gad did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    Protect Your Home From Medicaid Liens

    Plan ahead for long-term care needs to protect your home and your estate.
  3. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  4. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  8. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  9. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!